Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T+A+RAD in Metastatic HCC
NCT05396937Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Fudan University. Status: unknown.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05396937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05396937.